如何治疗儿童、青少年和年轻成人费城染色体样急性淋巴细胞白血病
费城染色体样急性淋巴细胞白血病(Ph-like ALL)是高风险B细胞谱系ALL亚型,尽管采用风险适应性多药化疗,无复发生存仍差。二代测序揭示了可用于个体化分子靶向治疗的激酶激活遗传驱动因素多样性。基于稳健的临床前数据和TKI在相关遗传亚型中显示临床活性的病例系列,多项临床试验研究了JAK或ABL定向TKI在CRLF2/JAK通路突变或ABL类Ph-like ALL中的疗效,最终结果待报告,标准治疗方案尚未定义。本文通过儿童、青少年和年轻成人新诊断或复发/难治性Ph-like ALL的示例性临床病例,回顾近期文献以指导当前循证治疗建议,并强调针对该高风险人群的免疫治疗和TKI的开放和即将开放的试验。
要点
- Ph-like ALL是高风险B-ALL亚型,风险适应性多药化疗下无复发生存仍差。
- 二代测序揭示Ph-like ALL激酶激活遗传驱动多样性,潜在可行个体化分子靶向治疗。
- JAK或ABL定向TKI在CRLF2/JAK通路突变或ABL类Ph-like ALL中的临床试验最终结果待报告,标准治疗尚未定义。
核心结论
- Ph-like ALL标准治疗方案尚未定义,当前治疗建议基于近期文献证据。
研究设计与样本
- 本文为How I Treat观点综述,通过示例性临床病例回顾近期文献以指导当前循证治疗建议。
主要发现
- Ph-like ALL为高风险B细胞谱系ALL亚型,尽管采用风险适应性多药化疗,无复发生存仍差。
- 二代测序揭示了Ph-like ALL中可用于个体化分子靶向治疗的激酶激活遗传驱动因素多样性。
- 基于稳健临床前数据和TKI在相关遗传亚型成人和儿童中显示临床活性的病例系列,多项临床试验研究了JAK或ABL定向TKI在CRLF2/JAK通路突变或ABL类Ph-like ALL中的疗效。
- 这些试验的最终结果待报告。
关键数值与推荐
- JAK定向TKI用于细胞因子受体样因子2(CRLF2)/JAK通路突变Ph-like ALL。
- ABL定向TKI用于ABL类Ph-like ALL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些试验的最终结果待报告。
- Ph-like ALL的标准治疗尚未定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) represents a high-risk B-lineage ALL subtype characterized by adverse clinical features and poor relapse-free survival despite risk-adapted multiagent chemotherapy regimens. The advent of next-generation sequencing has unraveled the diversity of kinase-activating genetic drivers in Ph-like ALL that are potentially amenable to personalized molecularly-targeted therapies. Based upon robust preclinical data and promising case series of clinical activity of tyrosine kinase inhibitor (TKI)-based treatment in adults and children with relevant genetic Ph-like ALL subtypes, several clinical trials have investigated the efficacy of JAK- or ABL-directed TKIs in cytokine receptor-like factor 2 (CRLF2)/JAK pathway-mutant or ABL-class Ph-like ALL, respectively. The final results of these trials are pending, and standard-of-care therapeutic approaches for patients with Ph-like ALL have yet to be defined. In this How I Treat perspective, we review recent literature to guide current evidence-based treatment recommendations via illustrative clinical vignettes of children, adolescents, and young adults with newly diagnosed or relapsed/refractory Ph-like ALL, and we further highlight open and soon-to-open trials investigating immunotherapy and TKIs specifically for this high-risk patient population.
引用
- Tran TH, Tasian SK. How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults. Blood. 2025. PMID: 38657263. doi:10.1182/blood.2023023153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。